

David M Gershenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2256514/publications.pdf>

Version: 2024-02-01

122
papers

8,567
citations

31902

53
h-index

46693

89
g-index

123
all docs

123
docs citations

123
times ranked

5562
citing authors

#	ARTICLE	IF	CITATIONS
1	Grading Ovarian Serous Carcinoma Using a Two-Tier System. <i>American Journal of Surgical Pathology</i> , 2004, 28, 496-504.	2.1	592
2	Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 134-140.	5.1	322
3	Management of Ovarian Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2938-2943.	0.8	268
4	Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 930-936.	0.8	247
5	Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2006, 108, 361-368.	1.2	242
6	Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. <i>Gynecologic Oncology</i> , 2009, 114, 48-52.	0.6	234
7	A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. <i>Cancer</i> , 2010, 116, 5415-5419.	2.0	222
8	Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. <i>Obstetrics and Gynecology</i> , 2002, 99, 3-10.	1.2	204
9	Sexual dysfunction and treatment for early stage cervical cancer. <i>Cancer</i> , 1989, 63, 204-212.	2.0	203
10	Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , 2008, 108, 510-514.	0.6	203
11	Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 2676-2676.	0.8	199
12	Ovarian serous borderline tumors with invasive peritoneal implants. <i>Cancer</i> , 1998, 82, 1096-1103.	2.0	186
13	Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2792-2797.	0.8	172
14	Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2670-2670.	0.8	168
15	Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , 2012, 125, 661-666.	0.6	166
16	Serous borderline tumors of the ovary with noninvasive peritoneal implants. <i>Cancer</i> , 1998, 83, 2157-2163.	2.0	162
17	The Recurrence and the Overall Survival Rates of Ovarian Serous Borderline Neoplasms With Noninvasive Implants is Time Dependent. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1367-1371.	2.1	162
18	Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?. <i>Gynecologic Oncology</i> , 2009, 113, 86-90.	0.6	153

#	ARTICLE	IF	CITATIONS
19	Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer. <i>Annals of Internal Medicine</i> , 2000, 132, 364.	2.0	149
20	Outcome and reproductive function after conservative surgery for borderline ovarian tumors. <i>Obstetrics and Gynecology</i> , 2000, 95, 541-547.	1.2	146
21	Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2007, 105, 404-408.	0.6	126
22	Prognosis of surgically determined complete responders in advanced ovarian cancer. <i>Cancer</i> , 1985, 55, 1129-1135.	2.0	120
23	The current status of surgical staging of ovarian serous borderline tumors. , 1999, 85, 905-911.		120
24	Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation. <i>Gynecologic Oncology</i> , 2009, 115, 6-11.	0.6	111
25	Microscopic disease at second-look laparotomy in advanced ovarian cancer. <i>Cancer</i> , 1985, 55, 472-478.	2.0	107
26	Endodermal sinus tumor of the vagina and cervix. <i>Cancer</i> , 1985, 55, 2558-2565.	2.0	104
27	Ovarian Carcinomas with Transitional Cell Carcinoma Patter. <i>American Journal of Clinical Pathology</i> , 1990, 93, 457-465.	0.4	101
28	Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. <i>Journal of Clinical Oncology</i> , 2015, 33, 2675-2682.	0.8	91
29	Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. <i>Cancer</i> , 2016, 122, 230-237.	2.0	91
30	Fertility-Sparing Surgery for Malignancies in Women. <i>Journal of the National Cancer Institute Monographs</i> , 2005, 2005, 43-47.	0.9	89
31	Reflectance spectroscopy for in vivo characterization of ovarian tissue. <i>Lasers in Surgery and Medicine</i> , 2001, 28, 56-66.	1.1	88
32	DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. <i>Gynecologic Oncology</i> , 2017, 147, 521-527.	0.6	87
33	MEK inhibitor resistance mechanisms and recent developments in combination trials. <i>Cancer Treatment Reviews</i> , 2021, 92, 102137.	3.4	85
34	Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. <i>Cancer</i> , 1985, 56, 2756-2761.	2.0	84
35	The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 3517-3523.	0.8	82
36	Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. <i>Gynecologic Oncology</i> , 2009, 114, 431-436.	0.6	82

#	ARTICLE	IF	CITATIONS
37	ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 16951-16963.	0.8	82
38	Survival in Women With Grade 1 Serous Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2013, 122, 225-232.	1.2	78
39	Prevalence of Lymph Node Metastasis in Primary Mucinous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2010, 116, 269-273.	1.2	76
40	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 541-553.	6.3	75
41	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020, 156, 715-725.	0.6	74
42	Sexual adjustment of patients undergoing Gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. <i>Cancer</i> , 1996, 78, 2229-2235.	2.0	73
43	Management of borderline ovarian tumours. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 49-59.	1.4	73
44	Clinical management potential tumours of low malignancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 513-527.	1.4	71
45	Efficacy and safety of bevacizumab in recurrent sex cordâ€stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group. <i>Cancer</i> , 2014, 120, 344-351.	2.0	71
46	Ovarian Sex Cord-Stromal Tumors. <i>Journal of Oncology Practice</i> , 2016, 12, 940-946.	2.5	71
47	Comparison of the clinical behavior of newly diagnosed stages IIâ€“IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 625-629.	0.6	69
48	Salvage Surgery for Chemorefractory Ovarian Germ Cell Tumors. <i>Gynecologic Oncology</i> , 1994, 55, 217-223.	0.6	64
49	Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all. <i>Gynecologic Oncology</i> , 2015, 136, 373-383.	0.6	64
50	Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. <i>British Journal of Cancer</i> , 2015, 113, 1254-1258.	2.9	63
51	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249.	0.6	61
52	Mucinous tumors of the ovary. A clinicopathologic study of 70 cases. <i>Cancer</i> , 1985, 55, 1958-1962.	2.0	59
53	Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. <i>Gynecologic Oncology</i> , 2012, 125, 515-517.	0.6	57
54	Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin. <i>Cancer</i> , 1986, 57, 1731-1737.	2.0	54

#	ARTICLE	IF	CITATIONS
55	The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. <i>Gynecologic Oncology</i> , 2015, 136, 25-29.	0.6	51
56	Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. <i>Gynecologic Oncology</i> , 2017, 145, 37-40.	0.6	51
57	Alveolar rhabdomyosarcoma of the female genitalia. <i>Cancer</i> , 1985, 56, 849-855.	2.0	49
58	Second-Look Laparotomy in the Management of Malignant Germ Cell Tumors of the Ovary. <i>Obstetrics and Gynecology</i> , 1986, 67, 789-793.	1.2	49
59	Treatment of Ovarian Cancer in Young Women. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 65-74.	0.6	47
60	Contemporary Treatment of Borderline Ovarian Tumors. <i>Cancer Investigation</i> , 1999, 17, 206-210.	0.6	45
61	Fluorescence spectroscopy for in vivo characterization of ovarian tissue. <i>Lasers in Surgery and Medicine</i> , 2001, 29, 128-135.	1.1	44
62	Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). <i>Gynecologic Oncology</i> , 2018, 150, 9-13.	0.6	44
63	Low-grade serous primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2011, 121, 482-486.	0.6	42
64	Quality of life in long-term survivors of ovarian germ cell tumors: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2007, 105, 687-694.	0.6	41
65	Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma: Potential for cure and preservation of reproductive capacity. <i>Cancer</i> , 1986, 58, 2594-2599.	2.0	40
66	KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. <i>Nature Communications</i> , 2018, 9, 2496.	5.8	39
67	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	2.0	39
68	Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. <i>PLoS ONE</i> , 2015, 10, e0135101.	1.1	38
69	Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4142-4149.	0.8	37
70	FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 147, 3-10.	0.6	36
71	Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. <i>Molecular and Cellular Biochemistry</i> , 2001, 217, 21-33.	1.4	35
72	Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. <i>Oncotarget</i> , 2016, 7, 56933-56943.	0.8	34

#	ARTICLE	IF	CITATIONS
73	Infusion site soft-tissue injury after paclitaxel administration. <i>Cancer</i> , 1995, 76, 116-120.	2.0	33
74	Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. <i>Cancer</i> , 1986, 58, 1407-1410.	2.0	30
75	Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment. <i>Gynecologic Oncology</i> , 2016, 143, 428-432.	0.6	30
76	Prognostic factors in stage II endometrial carcinoma. <i>Cancer</i> , 1987, 60, 1358-1361.	2.0	29
77	Trends of low-grade serous ovarian carcinoma in the United States. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e15.	1.0	29
78	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. <i>Gynecologic Oncology</i> , 2020, 158, 653-658.	0.6	29
79	Calcifications in Ovary and Endometrium and Their Neoplasms. <i>Modern Pathology</i> , 2003, 16, 219-222.	2.9	28
80	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2017, 144, 496-502.	0.6	27
81	Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 459-468.	2.0	25
82	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord Stromal Tumors: A Contemporary Review. <i>Cancers</i> , 2020, 12, 1398.	1.7	24
83	Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2014, 133, 100-104.	0.6	22
84	Nature of cervical involvement in endometrial carcinoma. <i>Cancer</i> , 1987, 59, 959-962.	2.0	19
85	Management of Rare Ovarian Cancer Histologies. <i>Journal of Clinical Oncology</i> , 2019, 37, 2406-2415.	0.8	19
86	Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 87-93.	0.3	18
87	Treatment of Rare Epithelial Ovarian Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1011-1024.	0.9	16
88	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. <i>Gynecologic Oncology</i> , 2019, 153, 230-237.	0.6	16
89	The Life and Times of Low-Grade Serous Carcinoma of the Ovary. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e195-e199.	1.8	16
90	Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors. <i>Journal of Surgical Oncology</i> , 1994, 10, 290-298.	1.4	13

#	ARTICLE	IF	CITATIONS
91	Pharmacoeconomic Considerations in Treating Ovarian Cancer. <i>Pharmacoeconomics</i> , 2000, 17, 133-150.	1.7	13
92	Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. <i>Abdominal Radiology</i> , 2016, 41, 1589-1595.	1.0	13
93	Evolving population-based statistics for rare epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2020, 157, 3-11.	0.6	13
94	MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2020, 38, 3731-3734.	0.8	10
95	On-Site Fertility Preservation Services for Adolescents and Young Adults in a Comprehensive Cancer Center. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 229-234.	0.7	9
96	Low grade serous ovarian carcinoma: identifying variations in practice patterns. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 174-180.	1.2	9
97	The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy. <i>Cancers</i> , 2020, 12, 3043.	1.7	9
98	Clinical trial methodology in rare gynecologic tumor research: Strategies for success. <i>Gynecologic Oncology</i> , 2018, 149, 605-611.	0.6	8
99	Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 236-244.	0.8	8
100	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. <i>Gynecologic Oncology</i> , 2020, 157, 21-28.	0.6	8
101	Significance of lymph node ratio on survival of women with borderline ovarian tumors. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1289-1298.	0.8	8
102	The Life and Times of Low-Grade Serous Carcinoma of the Ovary. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e195-e199.	1.8	7
103	Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series. <i>Gynecologic Oncology Reports</i> , 2015, 13, 36-39.	0.3	6
104	Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations. <i>Scientific Reports</i> , 2020, 10, 20678.	1.6	6
105	Irinotecan in epithelial ovarian cancer. <i>Oncology</i> , 2002, 16, 29-31.	0.4	6
106	Ovarian serous borderline tumors with invasive peritoneal implants. <i>Cancer</i> , 1998, 82, 1096-1103.	2.0	5
107	Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. <i>Modern Pathology</i> , 2004, 17, 75-80.	2.9	5
108	A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. <i>Cancer</i> , 1999, 86, 2291-2300.	2.0	4

#	ARTICLE	IF	CITATIONS
109	Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 1733-1737.	1.2	4
110	Fertility preservation in rare ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 432-441.	1.2	4
111	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecologic Oncology, 2021, 162, 728-734.	0.6	4
112	Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors. Gynecologic Oncology, 2020, 159, 601-603.	0.6	3
113	Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. International Journal of Gynecological Cancer, 2020, 30, 1768-1774.	1.2	2
114	Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature. Gynecologic Oncology Reports, 2020, 32, 100576.	0.3	2
115	Rare Gynecologic Tumors: Coming of Age. Gynecologic Oncology, 2020, 157, 1-2.	0.6	2
116	Ovarian mucinous neoplasms, intestinal type, in premenopausal patients, develop in abnormal ovaries. Human Pathology, 2021, 108, 32-41.	1.1	2
117	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
118	Sex cord-stromal tumors of the ovary: road map for progress. International Journal of Gynecological Cancer, 2021, 31, 169-170.	1.2	2
119	Complete Resection Is Essential in the Surgical Treatment of Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2018, 28, 1453-1460.	1.2	1
120	Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum. Gynecologic Oncology Reports, 2020, 34, 100670.	0.3	1
121	HER-2/ neu peptide specificity in the recognition of HLA-A2 by natural killer cells. Cancer Immunology, Immunotherapy, 1999, 48, 401-410.	2.0	0
122	Contemporary Treatment Strategies for Rare Epithelial Ovarian Cancers. Current Obstetrics and Gynecology Reports, 2017, 6, 228-236.	0.3	0